論文

査読有り 国際誌
2020年5月

Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study.

Hepatology research : the official journal of the Japan Society of Hepatology
  • Asahiro Morishita
  • ,
  • Chikara Ogawa
  • ,
  • Akio Moriya
  • ,
  • Joji Tani
  • ,
  • Hirohito Yoneyama
  • ,
  • Koji Fujita
  • ,
  • Makoto Oryu
  • ,
  • Tomonori Senoo
  • ,
  • Koichi Takaguchi
  • ,
  • Tsutomu Masaki

50
5
開始ページ
557
終了ページ
564
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1111/hepr.13482

AIM: The incidence of hepatitis C virus (HCV) infection is much higher in hemodialysis patients than that in healthy individuals. The prognosis of hemodialysis patients with HCV infection is poorer than that without HCV infection. Therefore, antiviral intervention is pivotal for HCV infection in hemodialysis patients. Recent evaluations of the pangenotypic regimen of glecaprevir/pibrentasvir show that it is highly effective and safe for HCV-infected hemodialysis patients. However, a few reports showed that the effect of HCV elimination by glecaprevir/pibrentasvir improved liver dysfunction or anemia. The aim of the present study was to determine clinical outcomes after HCV elimination using the glecaprevir/pibrentasvir regimen in HCV-infected hemodialysis patients. METHODS: This study was a retrospective, six-center study conducted in Japan, in which 24 hemodialysis patients with HCV genotype 1-2 treated with glecaprevir/pibrentasvir were recruited. Blood examinations were performed at end of treatment (EOT), and at 3, 6, and 12 months post-treatment during the 12-month follow-up period. RESULTS: The overall sustained virologic response rate was 100% (24/24). During the DAA treatment period, adverse events were observed in 20.8% of patients (5/24), and pruritus was the most frequently observed in 12.5% (3/24). Interestingly, we observed an improved control of anemia after EOT with a significant increase in hemoglobin levels. In addition, total bilirubin was diminished, and platelet counts and albumin, total cholesterol, and alpha-fetoprotein levels remained unchanged after EOT in hemodialysis patients. Furthermore, erythropoietin concentration was not increased after EOT. CONCLUSIONS: HCV elimination using glecaprevir/pibrentasvir treatment might be a major breakthrough for the control of anemia in hemodialysis patients.

リンク情報
DOI
https://doi.org/10.1111/hepr.13482
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/31883211

エクスポート
BibTeX RIS